Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 34
Filter
1.
World J Clin Cases ; 11(16): 3899-3906, 2023 Jun 06.
Article in English | MEDLINE | ID: mdl-37383118

ABSTRACT

BACKGROUND: Perinatal brain injury may lead to later neurodevelopmental disorders, whose outcomes may vary due to neuroplasticity in young children. Recent neuroimaging studies have shown that the left parietotemporal area (which includes the left inferior parietal lobe) is associated with phonological awareness and decoding skills, which are essential skills for reading acquisition in children. However, the literature on the effect of perinatal cerebral injury on the development of phonological awareness or decoding ability in childhood is limited. CASE SUMMARY: We report the case of an 8-year-old boy who presented with reading difficulty following a perinatal injury in the parieto-temporal-occipital lobes. The patient was born at term and was treated for hypoglycemia and seizures during the neonatal period. Diffusion-weighted brain magnetic resonance imaging on postnatal day 4 revealed cortical and subcortical hyperintensities in the parieto-temporo-occipital lobe. At the age of 8 years, physical examination was unremarkable, aside from mild clumsiness. Despite occipital lobe injury, the patient had adequate visual acuity, normal eye movement, and no visual field defects. Full-scale intelligence quotient and verbal comprehension index on Wechsler Intelligence Scale for Children-Fourth Edition were 75 and 90, respectively. Further assessment revealed adequate recognition of Japanese Hiragana letters. However, he had significantly slower reading speed in the Hiragana reading test than control children. The phonological awareness test revealed significant errors (standard deviation +2.7) in the mora reversal task. CONCLUSION: Patients with perinatal brain injuries in the parietotemporal area require attention and may benefit from additional reading instructions.

2.
Genet Med ; 24(12): 2453-2463, 2022 12.
Article in English | MEDLINE | ID: mdl-36305856

ABSTRACT

PURPOSE: Cerebellar hypoplasia and atrophy (CBHA) in children is an extremely heterogeneous group of disorders, but few comprehensive genetic studies have been reported. Comprehensive genetic analysis of CBHA patients may help differentiating atrophy and hypoplasia and potentially improve their prognostic aspects. METHODS: Patients with CBHA in 176 families were genetically examined using exome sequencing. Patients with disease-causing variants were clinically evaluated. RESULTS: Disease-causing variants were identified in 96 of the 176 families (54.5%). After excluding 6 families, 48 patients from 42 families were categorized as having syndromic associations with CBHA, whereas the remaining 51 patients from 48 families had isolated CBHA. In 51 patients, 26 aberrant genes were identified, of which, 20 (76.9%) caused disease in 1 family each. The most prevalent genes were CACNA1A, ITPR1, and KIF1A. Of the 26 aberrant genes, 21 and 1 were functionally annotated to atrophy and hypoplasia, respectively. CBHA+S was more clinically severe than CBHA-S. Notably, ARG1 and FOLR1 variants were identified in 2 families, leading to medical treatments. CONCLUSION: A wide genetic and clinical diversity of CBHA was revealed through exome sequencing in this cohort, which highlights the importance of comprehensive genetic analyses. Furthermore, molecular-based treatment was available for 2 families.


Subject(s)
Exome , Nervous System Malformations , Child , Humans , Exome/genetics , Mutation , Nervous System Malformations/genetics , Atrophy/genetics , Folate Receptor 1/genetics , Kinesins
3.
Epilepsy Behav ; 125: 108397, 2021 12.
Article in English | MEDLINE | ID: mdl-34814035

ABSTRACT

PURPOSE: This multicenter study examined the effectiveness and tolerability of lacosamide (LCM) for children and young adults with epilepsy, particularly in patients who had previously been treated with other sodium channel blockers (SCBs) and the difference in effectiveness and tolerability when using other concomitant SCBs. METHODS: We retrospectively studied the clinical information of patients aged <30 years given LCM to treat epilepsy. The effectiveness and adverse events (AEs) of LCM and the other SCBs were investigated. Factors related to the effectiveness and AEs of LCM, such as the number of antiepileptic drugs (AEDs) tried before LCM and concomitantly used SCBs, were also studied. RESULTS: We enrolled 112 patients (median age = 11 years). One year after starting LCM, 29% of the patients were seizure free, and 50% had a ≥50% seizure reduction. Of the patients, 17% experienced AEs, the most common being somnolence. A ≥50% seizure reduction was observed for LCM in 30% of patients in whom other SCBs had not been effective. Lacosamide produced a ≥50% seizure reduction in 35% of the patients taking one concomitant SCB. By contrast, no patients had ≥50% seizure reduction, and 33% developed AEs, when LCM was administered concomitantly with two SCBs. CONCLUSIONS: Lacosamide was effective in 30% of children and young adults in whom other SCBs had not been effective. The effectiveness of LCM may differ from that of other SCBs, and it is worth trying in patients with epilepsy resistant to other AEDs.


Subject(s)
Acetamides , Sodium Channel Blockers , Acetamides/therapeutic use , Anticonvulsants/therapeutic use , Child , Humans , Lacosamide/therapeutic use , Retrospective Studies , Sodium Channel Blockers/therapeutic use , Treatment Outcome , Young Adult
4.
Mol Genet Metab Rep ; 29: 100805, 2021 Dec.
Article in English | MEDLINE | ID: mdl-34646736

ABSTRACT

Arginase 1 (ARG1) deficiency is a rare urea cycle disorder (UCD), with an estimated frequency of 1 per 2,200,000 births in Japan. Patients with ARG1 deficiency develop symptoms in late infancy or pre-school age with progressive neurological manifestations and sometimes present with severe hepatic disease. We previously investigated the status of UCDs in Japan; however, only one patient was identified as having ARG1 deficiency. Therefore, we aimed to investigate the current status of patients with ARG1 deficiency in 2018-2021 because almost 10 years have passed since the previous study. We present the disease history, clinical outcome, and treatment of five surviving patients with ARG1 deficiency and discuss the features of ARG1 deficiency in Japan. We found that clinicians often face difficulty in diagnosing ARG1 deficiency at the early stage of onset because of interpatient variability in onset time and clinical manifestations. Blood L-arginine and guanidino compounds were considered to be the major factors causing adverse neurodevelopmental outcomes. Therefore, early detection and intervention of ARG1 deficiency is essential for improved neurodevelopmental outcomes. Liver transplantation has been considered an effective treatment option that can dramatically improve the quality of life of patients, prior to the neurological manifestation of symptoms caused by ARG1 deficiency.

5.
J Hum Genet ; 66(12): 1193-1197, 2021 Dec.
Article in English | MEDLINE | ID: mdl-34211110

ABSTRACT

Heterozygous variants in TUBB encoding one of ß-tubulin isotypes are known to cause two overlapping developmental brain disorders, complex cortical dysplasia with other brain malformations (CDCBM) and congenital symmetric circumferential skin creases (CSCSC). To date, six cases of CSCSC and eight cases of CDCBM caused by nine heterozygous variants have been reported. Here we report two cases with novel de novo missense TUBB variants (NM_178014.4:c.863A>G, p.(Glu288Gly) and c.869C>T, p.(Thr290Ile)). Case 1 presented brain malformations consistent with tubulinopathies including abnormalities in cortex, basal ganglia, corpus callosum, brain stem, and cerebellum along with other systemic features such as coloboma, facial dysmorphisms, vesicoureteral reflux, hypoplastic kidney, and cutis laxa-like mild skin loosening. Another case presented abnormalities of the corpus callosum, brain stem, and cerebellum along with facial dysmorphisms. We reviewed previous literature and suggest the diversity of clinical findings of TUBB-related disorders.


Subject(s)
Brain/abnormalities , Genetic Association Studies , Genetic Predisposition to Disease , Mutation , Nervous System Malformations/diagnosis , Nervous System Malformations/genetics , Tubulin/genetics , Alleles , Genotype , Humans , Phenotype , Tubulin/metabolism
6.
Epilepsia Open ; 6(2): 402-412, 2021 Jun.
Article in English | MEDLINE | ID: mdl-34095686

ABSTRACT

OBJECTIVES: Long-term adrenocorticotropic therapy (LT-ACTH), which consisted of 2-4 weeks of daily injections of adrenocorticotropic hormone (ACTH) and subsequent months of weekly injections, was tried for relapsed West syndrome (WS) or other intractable epilepsies in small case reports. Our aim was to explore the efficacy of LT-ACTH for preventing WS relapse, as well as the prevalence of its adverse events. METHODS: This is a retrospective, nationwide, multicenter case series of patients with WS who underwent LT-ACTH. Clinical information of the patients and protocol of LT-ACTH were collected from participating institutes in this study. We defined clinical response to ACTH as achievement of hypsarrhythmia and epileptic spasms resolution. Patients who responded to daily ACTH injections were identified and assessed whether they experienced WS relapse during/after the weekly ACTH injection period. The outcome was measured by the nonrelapse rate at 24 months after daily ACTH injections using the Kaplan-Meier method. RESULTS: Clinical information of 16 children with WS was analyzed. The median age at LT-ACTH initiation was 14.5 months (range: 7-68 months). Thirteen (81%) patients had previously undergone conventional ACTH treatment. The LT-ACTH regimens comprised a median of 16 days of daily injections (range: 11-28 days) and 10 months of weekly injections (range: 3-22 months). Seven patients experienced WS relapse during/after subsequent weekly ACTH period, and the nonrelapse rate at 24 months after daily injections was estimated at 60.6% (95% confidence interval: 32.3%-80.0%). Height stagnation, hypertension, and irritability were observed; lethal adverse events were not reported. SIGNIFICANCE: Our study firstly explored the efficacy of LT-ACTH for preventing WS relapse. LT-ACTH might be a treatment option for patients with relapsed or intractable WS; however, we note that our study is limited by its small sample size and the lack of an appropriate control group.


Subject(s)
Spasms, Infantile , Adrenocorticotropic Hormone/adverse effects , Adrenocorticotropic Hormone/therapeutic use , Child , Humans , Recurrence , Research , Retrospective Studies , Spasms, Infantile/drug therapy
7.
ACS Appl Mater Interfaces ; 12(8): 9489-9497, 2020 Feb 26.
Article in English | MEDLINE | ID: mdl-32013380

ABSTRACT

High vertical carrier mobilities in organic semiconductor films are a challenging issue for fundamentally improving the performance of vertical devices. To achieve improvement in the vertical direction, a reduced graphene oxide (rGO) template is used with pentacene and DNTT having a herringbone structure enabling two-dimensional (2D) transport in comparison with CuPc having a slipped-stack structure. A thin-film structure and the optoelectrical properties of the oriented films are investigated with respect to molecular structures and packing modes. The rGO template induces a "laid-down" herringbone structure for pentacene and DNTT with a face-on orientation. Our results reveal that intermolecular dispersion energy is an additional important factor to form face-on states of molecules and influences face-on ratios in the films on rGO. Vertical charge mobilities of the films are significantly enhanced by the rGO template. Particularly, the DNTT film with a laid-down herringbone structure produces a vertical mobility as high as 0.27 cm2 V-1 s-1, one of the highest values for ordinary thin films with several hundred nanometer thickness. These findings suggest that 2D transport is advantageous for vertical carrier transport also.

8.
Sci Rep ; 9(1): 10251, 2019 07 16.
Article in English | MEDLINE | ID: mdl-31312008

ABSTRACT

Information on palaeo-tsunami magnitude is scientifically and socially essential to mitigate tsunami risk. However, estimating palaeo-tsunami parameters (e.g., inundation distance) from sediments is not simple because tsunami deposits reflect complex transport processes. Here, we show a new approach to estimate tsunami inundation distance based on the mixture ratio of gravels from several sources in tsunami deposits. We measured the roundness of source gravels in modern beach and fluvial deposits in a coastal valley in Japan through image analysis and then calculated the mixture ratio of both sediment types in tsunami deposits. Normalising the mixture ratios by inundation distances revealed an abrupt change in the mixture ratio at a constant percentile, regardless of tsunami magnitude. This relation allowed estimation of the inundation distance of palaeo-tsunamis during the last 4000 years.

9.
Mol Genet Genomic Med ; 7(7): e00698, 2019 07.
Article in English | MEDLINE | ID: mdl-31106992

ABSTRACT

BACKGROUND: The tricarboxylic acid (TCA) cycle is a sequence of catabolic reactions within the mitochondrial matrix, and is a central pathway for cellular energy metabolism. Genetic defects affecting the TCA cycle are known to cause severe multisystem disorders. METHODS: We performed whole exome sequencing of genomic DNA of a patient with progressive cerebellar and cerebral atrophy, hypotonia, ataxia, seizure disorder, developmental delay, ophthalmological abnormalities and hearing loss. We also performed biochemical studies using patient fibroblasts. RESULTS: We identified new compound heterozygous mutations (c.1534G > A, p.Asp512Asn and c.1997G > C, p.Gly666Ala) in ACO2, which encodes aconitase 2, a component of the TCA cycle. In patient fibroblasts, the aconitase activity was reduced to 15% of that of the control, and the aconitase 2 level decreased to 36% of that of the control. As such a decrease in aconitase 2 in patient fibroblasts was partially restored by proteasome inhibition, mutant aconitase 2 was suggested to be relatively unstable and rapidly degraded after being synthesized. In addition, the activity of the father-derived variant of aconitase 2 (p.Gly666Ala), which had a mutation near the active center, was 55% of that of wild-type. CONCLUSION: The marked reduction of aconitase activity in patient fibroblasts was due to the combination of decreased aconitase 2 amount and activity due to mutations. Reduced aconitase activity directly suppresses the TCA cycle, resulting in mitochondrial dysfunction, which may lead to symptoms similar to those observed in mitochondrial diseases.


Subject(s)
Aconitate Hydratase/genetics , Brain Diseases/genetics , Cerebellum/pathology , Cerebrum/pathology , Mutation , Aconitate Hydratase/metabolism , Atrophy/genetics , Atrophy/pathology , Brain Diseases/pathology , Cells, Cultured , Cerebellum/metabolism , Cerebrum/metabolism , Child, Preschool , Female , Fibroblasts/metabolism , HEK293 Cells , Heterozygote , Humans
10.
RSC Adv ; 9(57): 32940-32945, 2019 Oct 15.
Article in English | MEDLINE | ID: mdl-35529162

ABSTRACT

A reduced graphene oxide (rGO) film is first applied to a surface template layer to control the molecular orientation of crystalline organic semiconductors. The ultrathin and ultrasmooth rGO layer was successfully prepared on a substrate without a transfer process by spin-coating a carefully purified GO aqueous dispersion. This rGO layer exhibited a strong templating effect rivaling monolayer graphene, inducing a face-on orientation of copper phthalocyanine molecules leading to significant improvement of vertical carrier mobilities. The highly-conductive and transparent rGO film does not hamper charge transport at the interface and photoabsorption unlike conventional templating materials. This method can be widely used for vertical organic devices that require high carrier mobilities and strong photoabsorption/emission.

11.
Brain Dev ; 40(10): 850-856, 2018 Nov.
Article in English | MEDLINE | ID: mdl-29908673

ABSTRACT

BACKGROUND: There are few studies on hiragana reading skill and phonological awareness in Japanese schoolchildren with periventricular leukomalacia (PVL). METHODS: Three seven-year-old children with PVL who had no intellectual disabilities or dysarthria were recruited. Their perinatal information, brain magnetic resonance image (MRI) at term equivalent age, accompanying neurodevelopmental disorders, ophthalmologic features, Kaufman Assessment Battery for Children (K-ABC), a hiragana reading test (four tasks), and a phonological awareness task (mora reversal tasks) were analyzed. RESULTS: Patient (Pt) 1 and pt2 were male. Pt2 and pt3 were siblings of triplets. Their gestational age was 28 or 32 weeks, and their birth weights were 1196, 1554, and 1848 g, respectively. Their brain MRI revealed cystic or non-cystic periventricular white matter injury involving the deep white matter at the trigone of both lateral ventricles. Pt1 had attention-deficit/hyperactivity disorder and pt3 had pervasive developmental disorder not otherwise specified. All patients had strabismus with spared best-corrected visual acuity. Scores of Reading/Decoding in K-ABC ranged from 89 to 99. As for the single mora reading task or the non-word reading task in the kana reading test, Z scores of their reading time ranged from 2.3 to 5.9 compared to control children. Pt1 and pt3 made significant errors in the mora reversal task of three-mora words, whereas all patients could answer all words correctly in the mora reversal task of two-mora words. CONCLUSION: All children showed significantly prolonged reading time despite their adequate letter recognition. Two patients showed delayed phonological awareness. It was suggested that hiragana decoding impairment due to subcortical and/or cortical injury related to PVL affected their reading ability.


Subject(s)
Dyslexia/physiopathology , Leukomalacia, Periventricular/physiopathology , Pattern Recognition, Visual/physiology , Reading , Child , Dyslexia/etiology , Female , Gestational Age , Humans , Infant, Newborn , Infant, Premature , Infant, Premature, Diseases , Leukomalacia, Periventricular/complications , Male , Triplets
12.
Brain Dev ; 39(8): 672-677, 2017 Sep.
Article in English | MEDLINE | ID: mdl-28404210

ABSTRACT

BACKGROUND: The characteristics of epilepsy in patients with Kabuki syndrome with KMT2D mutations (KABUK1) have not yet been well documented. This is the first review to explore this. MATERIALS & METHODS: We enrolled 14 patients with KABUK1, whose median age was 13.6years (range=4.1-21.3years). Their medical records from October 1981 to May 2016 were retrospectively analyzed. RESULTS: Epilepsy was present in 5 (36%) patients. Four of these patients presented with nonsense mutations and one with missense mutations. None presented with brain abnormalities. Four patients presented with annual or monthly focal seizures, of which three evolved to bilateral convulsive seizures. Median onset age of focal epilepsy was 11.8years (range=9.5-12.8years). One presented with monthly myoclonic seizures from age 11.2, whose mother with no other KABUK1 features, had focal epilepsy. The cumulative incidence of epilepsy related to KABUK1 up until age 13 was 45%. Interictal electroencephalogram revealed focal paroxysmal epileptiform discharges (in frontal, central, and parietal regions) in three patients, diffuse high-voltage spike-and-waves in one patient, and normal sleep record in one patient. Myoclonic seizures were rapidly controlled by levetiracetam. In contrast, focal seizures were not controlled in the early period of antiepileptic therapy. CONCLUSION: This long-term follow-up of patients with KABUK1 revealed a higher prevalence of epilepsy than previously reported. The age of epilepsy onset and rate of focal seizures evolving to bilateral convulsive seizures in KABUK1 were also higher than previously reported in patients with clinically diagnosed Kabuki syndrome. Although seizure outcome is reported to be favorable in Kabuki syndrome, focal seizures in patients with KABUK1 were not immediately responsive to medication.


Subject(s)
Abnormalities, Multiple/genetics , Abnormalities, Multiple/physiopathology , DNA-Binding Proteins/genetics , Epilepsy/genetics , Epilepsy/physiopathology , Face/abnormalities , Hematologic Diseases/genetics , Hematologic Diseases/physiopathology , Neoplasm Proteins/genetics , Vestibular Diseases/genetics , Vestibular Diseases/physiopathology , Abnormalities, Multiple/drug therapy , Abnormalities, Multiple/epidemiology , Adolescent , Age of Onset , Anticonvulsants/therapeutic use , Child , Child, Preschool , Epilepsy/drug therapy , Epilepsy/epidemiology , Face/physiopathology , Female , Follow-Up Studies , Hematologic Diseases/drug therapy , Hematologic Diseases/epidemiology , Humans , Incidence , Male , Mutation , Phenotype , Retrospective Studies , Vestibular Diseases/drug therapy , Vestibular Diseases/epidemiology , Young Adult
14.
J Hum Genet ; 62(5): 525-529, 2017 Apr.
Article in English | MEDLINE | ID: mdl-28077841

ABSTRACT

Here we present four unrelated families with six individuals that have infantile-onset developmental delay/regression and epilepsy. Whole-exome sequencing revealed compound heterozygous mutations, c.[283G>A];[607G>A] in a gene encoding prolyl-tRNA synthetase (PARS2) in one family. Two pairs of compound heterozygous mutations, c.[151C>T];[1184T>G] and c.[707T>G];[594+1G>A], and a homozygous mutation, c.[500A>G];[500A>G], in a gene encoding asparaginyl-tRNA synthetase (NARS2) were also identified in the other three families. Mutations in genes encoding aminoacyl-tRNA synthetases cause gene-specific mitochondrial disorders. Biallelic PARS2 or NARS2 mutations are reported to cause Alpers' syndrome, which is an autosomal recessive neurodegenerative disorder characterized by psychomotor regression and epilepsy with variable degree of liver involvement. Moreover, it is known that NARS2 mutations cause various clinical phenotypes, including non-syndromic hearing loss, Leigh syndrome, intellectual disability with epilepsy and severe myopathy. The individuals with PARS2 and NARS2 mutations, we have reported here demonstrate similar neurological features as those previously reported, with diversity in clinical presentation such as hearing loss and seizure type. Our data broaden the clinical and mutational spectrum of PARS2- and NARS2-related disorders.


Subject(s)
Amino Acyl-tRNA Synthetases/genetics , Aspartate-tRNA Ligase/genetics , Mutation/genetics , Neurodegenerative Diseases/genetics , Age of Onset , Child , Child, Preschool , Family , Female , Humans , Infant , Male , Pedigree
15.
Brain Dev ; 38(10): 954-958, 2016 Nov.
Article in English | MEDLINE | ID: mdl-27256512

ABSTRACT

Arts syndrome is characterized by early-onset hypotonia, ataxia, intellectual disability, sensorineural hearing impairment, progressive optic atrophy, and a tendency to develop infections. Arts syndrome is an X-linked disorder caused by a loss-of-function mutation in the PRPS1 gene, which encodes phosphoribosylpyrophosphate synthetase 1. Only three families have been reported. Here, we report another family with Arts syndrome. The initial symptoms of the 1-year-old proband were hypotonia and ataxia, worsening recurrent infection-triggered muscle weakness, motor and intellectual developmental delay, and hearing loss. Both central nervous system involvement and peripheral neuropathy were demonstrated. His three maternal uncles had died before the age of 3years. A genetic analysis of PRPS1 revealed a novel missense mutation, c.367C>G (p.His123Asp). PRPS enzymatic activity was markedly reduced in the patient. His mother was supposed to be an asymptomatic carrier. Arts syndrome should be included in the differential diagnosis of infantile hypotonia and weakness aggravated by recurrent infection with a family history of X-linked inheritance.


Subject(s)
Ataxia/genetics , Deaf-Blind Disorders/genetics , Genetic Diseases, X-Linked/genetics , Mutation, Missense , Ribose-Phosphate Pyrophosphokinase/genetics , Ataxia/diagnostic imaging , Ataxia/physiopathology , Ataxia/therapy , Brain/diagnostic imaging , Deaf-Blind Disorders/diagnostic imaging , Deaf-Blind Disorders/physiopathology , Deaf-Blind Disorders/therapy , Family , Genetic Diseases, X-Linked/diagnostic imaging , Genetic Diseases, X-Linked/physiopathology , Genetic Diseases, X-Linked/therapy , Humans , Infant , Male , Neural Conduction/genetics , Pedigree
16.
Brain Dev ; 38(8): 723-30, 2016 Sep.
Article in English | MEDLINE | ID: mdl-27033151

ABSTRACT

PURPOSE: Although it has been reported that some antiepileptic drugs have inducing or inhibiting effects on lamotrigine (LTG) clearance, whether they have the same effects in Asian epilepsy patients as in those in other countries has not been clarified, especially in children. The aim of this study was to determine the effects of co-medications on LTG clearance in Japanese children with epilepsy. METHODS: A total of 342 routine serum concentration measurements of LTG in 102 Japanese epilepsy patients under 20years of age were reviewed. The dose-corrected concentration (DCC) of LTG was calculated as [concentration]/[dose/(body weight)], and the DCC of LTG was compared by co-medication. The difference in the DCC of LTG was compared between patients with and without valproic acid (VPA) and between those with and without drugs inducing glucuronic acid conjugation (phenytoin (PHT), carbamazepine (CBZ), and phenobarbital (PB)). RESULTS: The DCC of LTG was significantly higher in patients on VPA and significantly lower in patients on drugs inducing glucuronic acid conjugation than in patients on LTG monotherapy. The DCC of LTG was significantly higher in patients on CBZ than in patients on PHT or PB. There was no correlation between the DCC of LTG and the concentration of VPA or metabolic inducers within the therapeutic range. Other antiepileptic drugs including clobazam, clonazepam, zonisamide, and levetiracetam had little effect on LTG concentration. CONCLUSION: LTG concentration changes dramatically with concomitant antiepileptic drugs in Japanese children, as previously reported from other countries, and special attention is required. Although the dose of LTG should be adjusted when starting or discontinuing VPA or metabolic inducers, no adjustment is needed when changing the dose of VPA or metabolic inducers in the therapeutic range.


Subject(s)
Anticonvulsants/pharmacokinetics , Epilepsy/blood , Epilepsy/drug therapy , Triazines/pharmacokinetics , Adolescent , Anticonvulsants/administration & dosage , Benzodiazepines/administration & dosage , Carbamazepine/administration & dosage , Child , Child, Preschool , Clobazam , Clonazepam/administration & dosage , Drug Interactions , Drug Therapy, Combination , Female , Humans , Infant , Infant, Newborn , Isoxazoles/administration & dosage , Japan , Lamotrigine , Levetiracetam , Male , Phenobarbital/administration & dosage , Phenytoin/administration & dosage , Piracetam/administration & dosage , Piracetam/analogs & derivatives , Triazines/administration & dosage , Valproic Acid/administration & dosage , Young Adult , Zonisamide
18.
Org Lett ; 17(24): 6158-61, 2015 Dec 18.
Article in English | MEDLINE | ID: mdl-26606580

ABSTRACT

Tandem intramolecular electrophilic arene borylation was developed to facilitate access to B-doped polycyclic aromatic hydrocarbons (PAHs). DFT calculations revealed that electrophilic arene borylation occurred via a four-membered ring transition state, in which C-B and H-Br bonds formed in a concerted manner. An organic light-emitting diode employing the B-doped PAH as an emitter and a B-doped PAH-based field-effect transistor were successfully fabricated, demonstrating the potential of B-doped PAHs in materials science.

19.
Pediatr Neurol ; 51(5): 701-5, 2014 Nov.
Article in English | MEDLINE | ID: mdl-25193414

ABSTRACT

BACKGROUND: We aimed to assess the characteristics of thalamic lesions in children with acute encephalopathy with biphasic seizures and late reduced diffusion. METHODS: Using the Tokai Pediatric Neurology Society database, we identified and enrolled 18 children with acute encephalopathy with biphasic seizures and late reduced diffusion from 2008 to 2010. Using diffusion-weighted images, we identified patients with thalamic lesions and compared their clinical factors with those of patients without thalamic lesions. We analyzed the time sequence of thalamic, sucortical, and cortical lesions. To study the topography of thalamic lesions, we divided the thalamus into five sections: anterior, medial, anterolateral, posterolateral, and posterior. Subsequently, we analyzed the relationship between the topography of thalamic lesions and the presence of central-sparing. RESULTS: Seven children presented with symmetrical thalamic lesions associated with bilateral subcortical or cortical lesions. No statistical difference in the clinical features was observed between individuals with and without thalamic lesions. These lesions were observed only when subcortical or cortical lesions were present. In 5 children, thalamic lesions were present in bilateral anterior or anterolateral sections and were associated with subcortical or cortical lesions in bilateral frontal lobes with central-sparing. In the other two children, thalamic lesions were extensive and accompanied by diffuse subcortical and cortical lesions without central-sparing. CONCLUSION: Thalamic lesions in patients with acute encephalopathy with biphasic seizures and late reduced diffusion involve the anterior sections. The thalamocortical network may play a role in development of thalamic lesions in patients with acute encephalopathy with biphasic seizures and late reduced diffusion.


Subject(s)
Brain Diseases/complications , Brain Diseases/pathology , Diffusion Magnetic Resonance Imaging , Seizures/etiology , Thalamus/pathology , Age Factors , Brain Mapping , Child, Preschool , Female , Humans , Image Processing, Computer-Assisted , Infant , Male , Retrospective Studies , Statistics, Nonparametric
20.
No To Hattatsu ; 46(4): 287-9, 2014 Jul.
Article in Japanese | MEDLINE | ID: mdl-25154226

ABSTRACT

A 3-year-old boy developed left-sided convergent strabismus one week after upper respiratory infection. All examinations, including analysis of cerebrospinal fluid, a tensilon test, and brain MRI, were negative. He was diagnosed with idiopathic sixth nerve palsy. His symptom resolved gradually with vitamin B12, and remitted completely three months after onset. At the age of 6 years, he experienced recurrence of left-sided sixth nerve palsy. After vitamin B12 failed, his symptom responded markedly to intravenous steroid pulse therapy starting on day 26 after relapse. He has been symptom-free for three years since the second remission. Steroid therapy might be effective, and should be considered in children with idiopathic sixth nerve palsy who do not show spontaneous remission.


Subject(s)
Abducens Nerve Diseases/drug therapy , Methylprednisolone/therapeutic use , Child , Humans , Infusions, Intravenous , Male , Methylprednisolone/administration & dosage , Pulse Therapy, Drug , Recurrence
SELECTION OF CITATIONS
SEARCH DETAIL
...